This is a marketing communication and should not be taken as investment advice, personal recommendation, or an offer of, or a solicitation to, buy or sell, any financial instruments. This material has been prepared without regard to any particular investment objectives or financial situation, and has not been prepared in accordance with the legal and regulatory requirements to promote independent research. Any references to past or future performance of a financial instrument, index, or packaged investment product are not, and should not be taken as a reliable indicator of future results.
Amega Global Ltd is an investment company authorised and regulated under the Financial Services Commission, Mauritius, Investment Dealer Licence: GB22200548. Findeavour Ltd is authorised as a technology service provider to Amega Global Ltd. Company number 12971852, United Kingdom.
No services are provided to residents or citizens of the USA, North Korea, Iran, Mauritius and the Russian Federation. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please read and ensure you fully understand our Risk Disclosure Policy before investing.
Amega Global Ltd is an investment company authorised and regulated under the Financial Services Commission, Mauritius, Investment Dealer Licence: GB22200548. Findeavour Ltd is authorised as a technology service provider to Amega Global Ltd. Company number 12971852, United Kingdom.
No services are provided to residents or citizens of the USA, North Korea, Iran, Mauritius and the Russian Federation. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please read and ensure you fully understand our Risk Disclosure Policy before investing.
Amega © 2023 All Rights Reserved.
GBPUSD overview 29.03.2021
Sterling rises on vaccine relief.
GBPUSD under the bullish pressure today after decline in concerns about Britain’s COVID-19 vaccine supply from the European Union helped sterling reverse some of the currency’s earlier losses. The EU last week stopped short of imposing a ban on vaccine exports, a proposal that had caused concern in Britain – which has benefited the pound. The markets are currently focusing on the relative speed of vaccination programmes in Europe and UK – which is leading to expectations that Britain’s economy will reopen more quickly than European economies – which should widen the UK-EU gap in terms of recovery expectations and will, most likely, lead to further sterling gains in the near-term perspective.
Expect buyers on downward corrections.
Next resistance to watch – 1.3864
Trade with an award-winning broker! Lowest spreads on the market for Forex, Precious Metals, Energies. No re-quotes, no rejection of orders & instant withdrawals.
Open account
Latest Posts
Amega launches a brand new client area… and the crowd goes wild!
16 November 2023Amega reduces spreads up to 50%
25 September 2023Amega is going to the Traders Fair South Africa, 2023
14 September 2023Copycats: How social trading is changing the game.
18 July 2023BRENT 14.07.2023
14 July 2023Categories
Tags